Obi Griffith, PhD

Obi Griffith, PhD

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, Washington University School of Medicine

Research Interest

My research interests are best described as cancer informatics and clinical statistics with emphasis on use of high-throughput sequencing data in breast cancer. I use computational methods for the identification of molecular markers at the DNA, RNA and protein level that are useful for diagnosis, prognosis or predicting therapeutic response. My research focuses on understanding how changes in the coding and regulatory sequences of DNA contribute to cancer development and progression.

Education

  • 2008: PhD, medical genetics, University of British Columbia, Vancouver, British Columbia, Canada

Training

  • 2008 - 2010: Postdoctoral fellow, medical genetics, British Columbia Cancer Agency, Canada’s Michael Smith Genome Sciences Centre, Vancouver
  • 2010 - 2012: Postdoctoral fellow, cancer and DNA damage, Lawrence Berkeley National Laboratory, Berkeley, Calif.

Selected Research Publications

Genomic Data and Privacy.
  • Myers CT, Kumar RD, Pilgram L, [...] Griffith OL, [...] Gibbs RA
  • Clin Chem 2025
pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection.
  • Xia H, Hoang MH, Schmidt E, [...] Griffith OL, Griffith M
  • Genome Med 2024
A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges.
  • Gomez F, Danos AM, Del Fiol G, [...] Griffith OL
  • Cancer Discov 2024
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation.
  • Foltz JA, Tran J, Wong P, [...] Griffith OL, [...] Fehniger TA
  • Sci Immunol 2024
Single-cell T-cell receptor repertoire profiling in dogs.
  • Hoang MH, Skidmore ZL, Rindt H, [...] Griffith OL
  • Commun Biol 2024
DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms.
  • Cannon M, Stevenson J, Stahl K, [...] Griffith OL, [...] Wagner AH
  • Nucleic Acids Res 2024
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma.
  • Gomez F, Fisk B, McMichael JF, [...] Griffith OL
  • Cancer Res Commun 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
  • Wong P, Foltz JA, Chang L, [...] Griffith OL, [...] Fehniger TA
  • J Clin Invest 2023
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.
  • Chiorazzi M, Martinek J, Krasnick B, [...] Griffith O, [...] Flavell RA
  • J Immunother Cancer 2023
Computational prediction of MHC anchor locations guides neoantigen identification and prioritization.
  • Xia H, McMichael J, Becker-Hapak M, [...] Griffith OL, Griffith M
  • Sci Immunol 2023
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy.
  • Puig-Saus C, Sennino B, Peng S, [...] Griffith OL, [...] Ribas A
  • Nature 2023
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase.
  • Krysiak K, Danos AM, Saliba J, [...] Griffith OL
  • Nucleic Acids Res 2023
Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers.
  • Skidmore ZL, Kunisaki J, Lin Y, [...] Griffith OL
  • Cancer Genet 2022

View All Publications